Примери за използване на Live virus vaccines на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
If you are to be vaccinated by live virus vaccines.
How about live virus vaccines as seen in the rotavirus strains?
Exposure in utero to obinutuzumab and vaccination of infants with live virus vaccines.
Therefore, live virus vaccines should not be administered during therapy.
However, a history of contact dermatitis due to neomycin is not a contraindication to receiving live virus vaccines.
Live virus vaccines should not be given with this medicine or soon after you receive it.
Hizentra may impair the effect of some live virus vaccines such as measles, rubella, mumps and chicken pox.
The live virus vaccines against measles and mumps may produce such side effects as encephalitis.
HyQvia may reduce the effect of some virus vaccines such as measles, rubella, mumps andchicken pox(live virus vaccines).
Live virus vaccines should not be given for 3 months after receiving Rho(D) immune globulin.
M-M-RVAXPRO should be given concomitantly at separate injection sites, or one month before orafter administration of other live virus vaccines.
Therefore vaccination with live virus vaccines is not recommended whilst on Riximyo or whilst peripherally B cell depleted.
These synthetic particles elicit a strong immune response- comparable to that produced by live virus vaccines- but should be much safer, says KI's Darrell Irvine.
Immunisation with live virus vaccines is contraindicated due to the immunosuppression associated with Pixuvri therapy(see section 4.3).
In addition, you should not be around other persons living in your household who receive live virus vaccines because there is a chance they could pass the virus on to you.
Therefore vaccination with live virus vaccines is not recommended whilst on MabThera or whilst peripherally B cell depleted.
The safety of immunisation with live viral vaccines, following MabThera therapy has not been studied for NHL patients and vaccination with live virus vaccines is not recommended.
Live virus vaccines against paralytic poliomyelitis may in each instance produce the disease it is intended to prevent;
Treatment with Siklos andconcomitant immunisation with live virus vaccines should only be performed if benefits clearly outweigh potential risks.
Live virus vaccines(e.g., measles, mumps, rubella, varicella) should not be given within 3 months after receiving varicella-zoster immune globulin.
Treatment with hydroxycarbamide andconcomitant immunisation with live virus vaccines should only be performed if benefits clearly outweigh potential risks(see section 4.4).
Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during YESCARTA treatment, and until immune recovery following treatment with YESCARTA.
Consequently, newborns should be monitored for B-cell depletion and vaccinations with live virus vaccines should be postponed until the infant's B-cell count has recovered(see section 4.4).
While the use of live virus vaccines and immunization compared to other types of activation increases the risk of viruses and the development of infections.
If you have received a vaccination during the last six weeks and up to three months,the infusion of immunoglobulins like KIOVIG may impair the effect of some live virus vaccines such as measles, rubella, mumps and chicken pox.
Vaccination with live virus vaccines is not recommended during treatment and until B-cell recovery because of the immunosuppressive effect of obinutuzumab(see section 4.4).
Due to the potential depletion of B-cells in infants of mothers who have been exposed to Gazyvaro during pregnancy,infants should be monitored for B-cell depletion and vaccinations with live virus vaccines should be postponed until the infant's B-cell count has recovered.
It is advised to use live virus vaccines with caution after stopping chemotherapy, and vaccinate not sooner than 3 months after the last dose of chemotherapy see section.
Due to the potential depletion of B-cells in newborns following exposure to blinatumomab during pregnancy,newborns should be monitored for B-cell depletion and vaccinations with live virus vaccines should be postponed until the infant's B-cell count has recovered(see section 4.6).
Vaccination with live virus vaccines is not recommended for at least 2 weeks prior to the start of BLINCYTO treatment, during treatment, and until recovery of B-lymphocytes to normal ranges following last treatment cycle.